Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2023-10-20 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
(Revised) Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details repurchases of shares, cancellations, and confirmations related to these transactions. The document references compliance with listing rules of the Stock Exchange of Hong Kong and provides detailed transactional data on share repurchases and cancellations. There is no indication of financial statements, earnings data, management discussion, or other report types. The content is focused on reporting share repurchase activity and changes in capital structure. This matches the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length is substantial and contains detailed transactional data, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is POS with high confidence.
2023-10-20 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details repurchases of shares, cancellations, and confirmations related to share capital changes. The document references compliance with listing rules of the Stock Exchange of Hong Kong and provides detailed transactional data on share repurchases and cancellations. This type of document is a regulatory disclosure about share capital changes and repurchases, not a full financial report or earnings release. It fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2023-10-20 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details multiple repurchases of shares over various dates, including quantities and prices, and confirms compliance with listing rules. The content is focused on reporting share repurchase transactions and changes in issued shares, consistent with disclosures required by stock exchange rules. There is no indication of financial statements, management discussion, earnings data, or other report types. This matches the description of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length and detail confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2023-10-19 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details repurchases of shares on various dates, including quantities and prices, and confirms compliance with listing rules. The content is focused on reporting share repurchase transactions and changes in issued shares, which aligns with announcements of transactions in own shares. The document is about actual share repurchase activity, not a general announcement or a report publication. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length and detail support this classification with high confidence.
2023-10-18 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details multiple repurchases of shares over various dates, including quantities and prices, and confirms compliance with listing rules. The document is a regulatory disclosure about share repurchases and changes in issued shares, not a financial report or earnings release. It fits the definition of a 'Transaction in Own Shares' filing, which reports the company's buyback activities. The document length is substantial and contains detailed transactional data, confirming it is the report itself, not just an announcement. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2023-10-17 English
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR NEW INDICATION OF SIM0237 FOR INJECTION (ANTI-PD-L1/IL-15 BISPECIFIC ANTIBODY) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the clinical trial approval for a new indication of their drug SIM0237. It is an announcement about a regulatory approval from the National Medical Products Administration (NMPA) related to clinical trials. The document is relatively short (3671 characters) and does not contain financial data, financial statements, or detailed report content. It is not an annual report, earnings release, or any detailed financial or management report. It is also not a regulatory filing in the sense of officer certifications or compliance documents, but rather a business development announcement. Given the content and length, it fits best as a Regulatory Filings (RNS) type, which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2023-10-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.